Founder and Managing Partner of KerZheng Ventures. Venture Partner Aulis Capital Sr Partner Emeritus McKinsey. Based in Hong Kong for 20 yrs. Views are my own.
@biogerontology Why does he stick with this position. Which he already articulated at Jefferies NY a few months ago. There is no way his competition will be Chinese by that timeframe. Unless he means Chinese assets picked up by western competitors. Like the J&J deal yesterday
It’s more like 35B usd spent on innovative drugs for 1.4B people. Versus 415B for 330K people in the US. So 25 USD/capita versus 1250 usd/capita. A X50 ratio. Both those statements are true. Drug pricing is too low in China (driven by Gvt and Oktagon set up) and drug pricing is too high in the US (driven by inefficiencies and complexity of healthcare system).
Yes. Blank sheet players from ex US would be the beneficiaries. The benefits will be more at VC level than established European pharma. That’s why I find the US/EU framing too simplistic. Anyways, it could also be a negotiation move by Trump administration ahead of the next Xi/Trump meeting
There is what is written. And there is how it would be applied. I don’t believe for a second that a major European/UK/swiss biopharma would not be impacted. Not when over 55 pct of their business is US based (and much more of profits). Not to mention board composition or executive team make up.
For Bloomberg News Big Take, a deep dive on how biotech startups and pharma giants are increasingly taking trials to China early — and the new and complex challenges they pose.
with @ashleighfurlong@fabiennekatrin and team:
https://t.co/naQDXdfe0q
The U.S. Treasury is proposing new restrictions on investments in Chinese biotech, but traditional pharma licensing deals would largely be spared. Equity investments and certain partnerships could face significant hurdles. https://t.co/hG1MnVn85B
How did Hengrui become a go-to source of Chinese biopharma innovation? After multibillion-dollar deals with BMS and GSK, the company's R&D leader tells Fierce what's driving its success and where it goes next. https://t.co/gTVqh7R7p9
Roche is doubling down on China's Hansoh Pharma with a new ADC deal worth up to $15 billion in milestones. The pact comes just a year after the companies' first collaboration. https://t.co/qrvosmzILL $ROCH.NE
@JChanPharma A much more meaningful goal would be 5 innovative drugs with US1b in revenues in the China market. Even 0.5b. Here the US market is the driver of the bulk of sales. Also classifying BeOne as Chinese is a bit of a stretch…
@LifeSciVC@atlasventure Thanks for featuring my column for BioCentury, On balance, I think some fo the goals for 2030 are lofty, in particular FIC. Even counting BeOne as “Chinese” is a stretch. And it is so far the most successful example of “Chinese” expansion. But who cares about the exact date…
Europe’s narrow path between the U.S. and China in biotech https://t.co/SN57cY9FNi
I wrote this three months ago for BioCentury. It feels increasingly relevant, between the China 15 FYP for Biopharma, the letter from US CEOs asking Congress not to block China deals, and the letter from European Boards asking European leaders to wake up, or else…
@DaveARicks Sure Dave. But an industry that becomes even more US centric cannot be on solid footing for the long term. And surely, that can not be the core vision/mission for Big Pharma. At some level, the topic of affordability for much larger WW population has to be tackled.
« Il faut une première à tout et il faut une dernière pour se souvenir, une dernière, juste pour lui. ❤️ »
Merci à @ligue1plus pour LES ÉMOTIONS sur cette bande-annonce de Brest-PSG avec un hommage pour Éric Roy 🇫🇷. 🥹🕊️